Close
Achema middle east
swop processing & packaging

5-Year Kymriah Data Shows Long-Term Life In Kids And Teens

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

No New Drug Submissions by the FDA With Shutdown in Place

The Food and Drug Administration (FDA), which is already...

How to Tell if Your Loved One is Developing an Addiction

Watching a loved one change in ways you do...

The Future of Balding Treatments: What’s New in 2025

Are you balding or thinning out on top? It...

Novartis’ Kymriah created history five years ago when it became the first gene therapy to be licenced in the United States. As Novartis has attempted to increase its use in the lymphoma arena, the therapy has had its highs and lows. The company announced encouraging results from a long-term follow-up study of its use in its first approved indication on June 12th.

During the five-year research, 55% of 79 children and young adults with relapsed B-cell acute lymphoblastic leukaemia survived, with a 42% event-free survival rate. No response, rapid recurrence, or relapse from full remission are all examples of events used here.

The findings, reported at the European Hematology Association Hybrid Congress, demonstrate Kymriah’s therapeutic potential in a condition with few therapy options, according to Novartis. Patients had a five-year survival rate of less than 10% before Kymriah was approved, as per M.D., Ph.D., Director of the Susan S. and Stephen P. Kelly Center for Cancer Immunotherapy at Children’s Hospital of Philadelphia, Stephen Grupp. He says Kymriah is a game-changing alternative. Grupp noted that these findings are a source of great optimism because relapse after five years is quite unusual.

Within three months of infusion, 82% of patients demonstrated full remission or complete remission with partial hematologic recovery, according to the study. In addition, the five-year relapse-free survival percentage for patients in remission was 49%. Kymriah was approved by the FDA last month for relapsed or refractory follicular lymphoma. In 2018, the FDA approved it for select patients with large B-cell lymphoma in the United States.

The medication was predicted to work well in early-stage lymphoma, but it demonstrated no effect in severe B-cell non-Hodgkin’s lymphoma last year when compared to usual care. Meanwhile, Gilead’s Yescarta received approval in the indication in April this year, 14 months following Bristol Myers Squibb’s Breyanzi received permission.

Latest stories

Related stories

Lonza Widens Cell and Gene Therapy Suite with New Products

Lonza widens cell and gene therapy suite by way...

No New Drug Submissions by the FDA With Shutdown in Place

The Food and Drug Administration (FDA), which is already...

How to Tell if Your Loved One is Developing an Addiction

Watching a loved one change in ways you do...

The Future of Balding Treatments: What’s New in 2025

Are you balding or thinning out on top? It...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »